THE controversial trails of brothers Malvinder Singh and Shivinder Singh, who were previously the major shareholders of Fortis Heathcare Ltd, dates back to more than a decade ago when they sold their family’s stake in a pharmaceutical company.
Malvinder and younger brother Shivinder sold their 35% in Ranbaxy Laboratories in 2008 to Daiichi Sankyo, Japan’s third largest drug maker for about US$2.1bil.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
